MedIntelliBase
Logo
 
Neurology Example 6:
Pharmaceuticals: Ibuprofen

Please click here if you wish to skip directly to your Table of Contents listing the most recent Abstract Database additions.

Please click here if you wish to skip directly to the Table of Contents below. To learn more about our MedIntelliBase Custom Email Alerts, click here to complete our request form or contact us directly. Please click here to learn how to use this alert.

Table of Contents
  • Ibuprofen (Brufen)
  • Abbott Laboratories
    • Dalsy
  • ALTER FARMACIA
    • Narfen
  • Bausch & Lomb
    • Ibu-Vivimed
  • Bayer Pharmaceutical
    • Midol IB
    • Dorvial
  • Bergen Brunswig Drug Company
    • Cap-Profen
    • Tap-Profen
  • BEXAL FARMACEUTICA
    • Ibubex
  • Bristol-Myers Squibb
  • FARMASIERRA LABORATORIOS S.L.
    • Remidol
  • FARMA LEPORI
    • Feminalin
  • Intermed
    • Algofren
  • Knoll Pharmaceutical Company
    • Ibu
    • Rufen
    • Vicoprofen / hydrocodone-ibuprofen
  • LABORATORIOS ASOCIADOS NUPEL
    • Fiedosin
  • Major Pharmaceuticals
    • Childrens Ibuprofen Cold / ibuprofen and pseudoephedrine
    • Sup Pain Med
  • Marlop Pharmaceuticals Inc
    • Dolgesic
  • McNeil
    • Motrin Children Cold/ ibuprofen and pseudoephedrine
    • Motrin IB (1)
    • Motrin Children
    • Motrin Junior Strength
    • Motrin Infant
    • Motrin IB Sinus / ibuprofen-pseudoephedrine
    • Doctril
  • NORMON
    • Ibuprofeno Normon
  • OVATION Pharmaceuticals, Inc.
  • PDK Labs Inc
    • Advanced Pain Relief
  • Perrigo, L. Company
    • Childrens Ibuprofen Berry
    • Ibuprofen
  • Pfizer U.S. Pharmaceuticals Group
    • Pediacare
  • Ratiopharm GmbH
    • Ibu-ratiopharm
  • Reckitt Benckiser
    • Nurofen Cold and Flu / ibuprofen and pseudoephedrine
    • Nurofen Plus / ibuprofen and codeine
  • Roberts/Hauck Pharmaceutical Corporation
    • Saleto-200
    • Saleto-400
    • Saleto-600
    • Saleto-800
  • SALVAT
    • Salvarina
  • Schering-Phough
    • Alivium
  • United Research Laboratories / Mutual Pharmaceutical Company
    • Uni-Pro
  • Watson Pharmaceuticals
    • Menadol
    • Reprexain / ibuprofen and hydrocodone
  • Woelm Pharma GmbH & Co.
    • Dolormin
  • Wyeth Consumer Healthcare (1)
    • Advil (1)
    • Advil Allergy Sinus / ibuprofen, pseudoephedrine HCl, and chlorpheniramine maleate
    • Advil Cold & Sinus/ pseudoephedrine HCI and ibuprofen
    • Advil PM / Diphenhydramine citrate and ibuprofen
    • Advil Liqui-Gels
    • Advil Migraine
    • Advil Multi-Symptom Cold / ibuprofen, pseudoephedrine HCl, and chlorpheniramine maleate
Archived Abstracts

Go to Archive


Summary

Ibuprofen (Brufen)
Non-steroidal Anti-inflammatory Drug (NSAID) & Ibuprofen
Abstract Title Lead Author Publication Pub Date
Basophil activation test for the in vitro diagnosis of nonsteroidal anti-inflammatory drug hypersensitivity. Rodríguez-Trabado A Allergy Asthma Proc. 2008-05-01
Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Underwood M Health Technol Assess. 2008-05-01
Protective effects of NSAIDs on the development of Alzheimer disease. Vlad SC Neurology. 2008-05-06
Flexible porous metal-organic frameworks for a controlled drug delivery. Horcajada P J Am Chem Soc. 2008-05-03
Preparation and evaluation of immediate release ibuprofen solid dispersions using polyethylene glycol 4000. Newa M Biol Pharm Bull. 2008-05-01
Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. McCurnin D Pediatrics. 2008 May; 2008-05-01
Ibuprofen linked to reduced AD risk [none given] CNS Drug News Pharmaceuticals 2008-05-06
NSAIDS; Data on NSAIDS published by researchers at Kanazawa University [none given] Hospital Business Week 2008-05-04
ALZHEIMER DISEASE; Recent findings from University of Minnesota highlight research in Alzheimer disease [none given] Pharma Investments, Ventures & Law Weekly 2008-04-30
Ask the doctor.(Clinical report). Maurizio Fava. Mind, Mood & Memory 4.5: p8(1). 2008-05-01
Return to ToC
Pseudoephedrine & Ibuprofen
Alzheimer’s Disease & Ibuprofen
Abstract Title Lead Author Publication Pub Date
Health Buzz: Ibuprofen and Alzheimer's and Other Health News. January W. Payne U.S. News & World Report 2008-05-06
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. McKee AC Brain Res. 2008-05-01
Return to ToC
Age Onset Issue & Alzheimer's
Non-steroidal Anti-inflammatory Drug (NSAID) & Alzheimer's
Abbott Laboratories
Dalsy & Abbott
ALTER FARMACIA
Narfen & ALTER
Bausch & Lomb
Ibu-Vivimed & Bausch
Bayer Pharmaceutical
Midol IB & Bayer
Dorvial & Bayer
Bergen Brunswig Drug Company
Cap-Profen & Bergen
Tap-Profen & Bergen
BEXAL FARMACEUTICA
Ibubex & BEXAL
Bristol-Myers Squibb
Nuprin & Bristol-Myers
Abstract Title Lead Author Publication Pub Date
MEDICARE AND MEDICAID;Maryland Approves Medicaid Reimbursement for ActiPatch(R) [none given] Pharma Law Weekly 2008-05-06
Return to ToC
FARMASIERRA LABORATORIOS S.L.
Remidol & FARMASIERRA
FARMA LEPORI
Feminalin & FARMA
Intermed
Algofren & Intermed
Knoll Pharmaceutical Company
Ibu & Knoll
Rufen & Knoll
Vicoprofen / hydrocodone-ibuprofen & Knoll
LABORATORIOS ASOCIADOS NUPEL
Fiedosin & NUPEL
Major Pharmaceuticals
Childrens Ibuprofen Cold / ibuprofen and pseudoephedrine & Major Pharmaceuticals
Sup Pain Med & Major Pharmaceuticals
Marlop Pharmaceuticals Inc
Dolgesic & Marlop
McNeil
Motrin Children Cold/ ibuprofen and pseudoephedrine & McNeil
Motrin IB & McNeil
Abstract Title Lead Author Publication Pub Date
Scolr receives SPA to guide design of ER ibuprofen Phase III study [none given] Pharma Company Insight Pharmaceuticals 2008-05-01
Return to ToC
Motrin Children & McNeil
Motrin Junior Strength & McNeil
Motrin Infant & McNeil
Motrin IB Sinus / ibuprofen-pseudoephedrine & McNeil
Doctril & McNeil
NORMON
Ibuprofeno Normon & NORMON
OVATION Pharmaceuticals, Inc.
PDK Labs Inc
Advanced Pain Relief & PDK Labs
Perrigo, L. Company
Childrens Ibuprofen Berry & Perrigo
Ibuprofen & Perrigo
Pfizer U.S. Pharmaceuticals Group
Pediacare & Pfizer
Ratiopharm GmbH
Ibu-ratiopharm & Ratiopharm
Reckitt Benckiser
Nurofen Cold and Flu / ibuprofen and pseudoephedrine & Reckitt
Nurofen Plus / ibuprofen and codeine & Reckitt
Roberts/Hauck Pharmaceutical Corporation
Saleto-200 & Roberts/Hauck
Saleto-400 & Roberts/Hauck
Saleto-600 & Roberts/Hauck
Saleto-800 & Roberts/Hauck
SALVAT
Salvarina & SALVAT
Schering-Phough
Alivium & Schering-Phough
United Research Laboratories / Mutual Pharmaceutical Company
Uni-Pro & United Research
Watson Pharmaceuticals
Menadol & Watson
Reprexain / ibuprofen and hydrocodone & Watson
Woelm Pharma GmbH & Co.
Dolormin & Woelm
Wyeth Consumer Healthcare
Abstract Title Lead Author Publication Pub Date
16A Nonnarcotic analgesics.(SECTION 16: PAIN & PYREXIA). [none given] MPR Monthly Prescribing Reference 24.5: p316(5). 2008-05-01
Return to ToC
Advil & Wyeth
Abstract Title Lead Author Publication Pub Date
The Morning Call, Allentown, Pa., Spending Smart column: Change your brand allegiance Gregory Karp McClatchy-Tribune Regional News; The Morning Call, Allentown, Pa. 2008-05-04
Return to ToC
Advil Allergy Sinus / ibuprofen, pseudoephedrine HCl, and chlorpheniramine maleate & Wyeth
Advil Cold & Sinus/ pseudoephedrine HCI and ibuprofen & Wyeth
Advil PM / Diphenhydramine citrate and ibuprofen & Wyeth
Advil Liqui-Gels & Wyeth
Advil Migraine & Wyeth
Advil Multi-Symptom Cold / ibuprofen, pseudoephedrine HCl, and chlorpheniramine maleate & Wyeth

Full Abstracts

Ibuprofen (Brufen)
Non-steroidal Anti-inflammatory Drug (NSAID) & Ibuprofen

Basophil activation test for the in vitro diagnosis of nonsteroidal anti-inflammatory drug hypersensitivity.

Lead Author: Rodríguez-Trabado A

Additional Authors: Cámara-Hijón C, Ramos-Cantariño A, Porcel-Carreño SL, Jiménez-Timón S, Pereira-Navarro G, Hernández-Arbeiza FJ, Fernández-Pereira L.

Allergy Asthma Proc., 2008-05-01, 29(3):241-9.

Department of Allergy, University of Extremadura, Caceres, Spain. ana_rodriguez@ses.juntaex.es

There is need for an in vitro diagnostic test for hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs). The purpose of this study was to assess the reliability of one such diagnostic, the basophil activation test. Forty-three drug hypersensitive patients referring several immediate reactions (anaphylaxis, urticaria, angioedema, asthma, and rhinoconjunctivitis) to one or more NSAIDs and 29 controls participated. Using the Basotest commercial kit, 63 determinations were performed with the drugs implicated in the adverse reactions (ASA, ibuprofen, metamizol, diclofenac, paracetamol, and ketorolac). In 16 patients additional determinations were made with other chemically unrelated NSAIDs. Forty-two determinations were made for controls. The analysis was performed by flow colorimetric cytometry and double staining with the monoclonal antibodies anti-IgE and anti-CD63. A Basophil Activation Index (percentage of activated basophils after allergen stimulation/percentage of basally activated basophils) of two or more was considered a positive result. Specificity of 100% and sensitivity of 42.85% were achieved. The positive predictive value was 100%, and the negative predictive value was 53.84%. In 35.29% of intolerant patients there was a positive reaction to at least two drugs implicated in adverse reactions, and in 27.27% of these patients there was a positive reaction to other chemically unrelated NSAIDs. The basophil activation test is useful for the in vitro diagnosis of NSAID hypersensitivity, providing good specificity and positive predictive value and diagnostic reliability in the assessment of NSAID intolerance.

MIB Abstract ID Number: 15634

PreMedline Identifier: 18534081

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance

Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study.

Lead Author: Underwood M

Additional Authors: Ashby D, Carnes D, Castelnuovo E, Cross P, Harding G, Hennessy E, Letley L, Martin J, Mt-Isa S, Parsons S, Spencer A, Vickers M, Whyte K.

Health Technol Assess., 2008-05-01, 12(22):1-176.

Centre for Health Sciences, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, UK

OBJECTIVES: To determine whether GPs should advise their older patients with chronic knee pain to use topical or oral non-steroidal anti-inflammatory drugs (NSAIDs). DESIGN: An equivalence study was designed to compare the effect of advice to use preferentially oral or topical ibuprofen (an NSAID) on knee pain and disability, NSAID-related adverse effects and NHS/societal costs, using a randomised controlled trial (RCT) and a patient preference study (PPS). Reasons for patient preferences for topical or oral preparations, and attitudes to adverse effects, were explored in a qualitative study. SETTING: Twenty-six general practices in the UK. PARTICIPANTS: Participants comprised 585 people with knee pain, aged 50 years or over; 44% were male, mean age 64 years. The RCT had 282 participants: 144 in the oral group and 138 in the topical group. The PPS had 303 participants: 79 in the oral group and 224 in the topical group. INTERVENTIONS: Advice to use preferentially oral or topical NSAIDs for knee pain. OUTCOME MEASURES: The primary outcome measure was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcome measures were the Short Form with 36 Items (SF-36), perceived troublesomeness of knee pain, satisfaction with health status, major adverse effects (unplanned hospital admissions and deaths) and minor adverse events over 12 months. The health economic analysis measured the comparative cost per quality-adjusted life-year (QALY) from both an NHS and a societal perspective over 1 and 2 years. RESULTS: Changes in the global WOMAC score at 12-months were equivalent in both studies: topical - oral, RCT difference = 2 [95% confidence interval (CI) -2 to 6], PPS difference = 1 (95% CI -4 to 6). There were no differences in the secondary outcomes, except for a suggestion, in the RCT, that those in the topical group were more likely to have more severe overall pain and disability as measured by the chronic pain grade, and more likely to report changing treatment because of inadequate pain relief. There were no differences in the rate of major adverse effects but some differences in the number of minor ones. In the RCT, 17% and 10% in the oral and the topical group, respectively, had a defined respiratory adverse effect (95% CI of difference -17% to -2.0%); after 12 months, the change in serum creatinine was 3.7 mmol/l (95% CI 0.9 to 6.5) less favourable in the oral than in the topical group, and 11% of those in the oral group reported changing treatment because of adverse effects compared with 1% in the topical group (p = 0.02). None of these differences were seen in the PPS. Oral NSAIDs cost the NHS 191 pounds and 72 pounds more per participant over 1 year in the RCT and PPS respectively. In the RCT the cost per QALY in the oral group, from an NHS perspective, was in the range 9000-12,000 pounds. In the PPS it was 2564 pounds over 1 year, but over 2 years the oral route was more cost-effective. Patient preference for medication type was affected by previous experience of medication (including adverse reactions), other illness, pain elsewhere, anecdotes, convenience, severity of pain and perceived degree of degeneration. Lack of understanding about knee pain and the action of medication led to increased tolerance of symptoms. Potentially important symptoms may inadvertently have been disregarded, increasing participants' risk of suffering a major adverse effect. CONCLUSIONS: Advice to use either oral or topical preparations has an equivalent effect on knee pain, but oral NSAIDs appear to produce more minor adverse effects than topical NSAIDs. Generally, these results support advising older people with knee pain to use topical rather than oral NSAIDS. However, for patients who prefer oral NSAID preparations rather than a topical NSAID, particularly those with more widespread or severe pain, the oral route is a reasonable treatment option, provided that patients are aware of the risks of potentially serious adverse effects from oral medication. Further research is needed into strategies to change prescribing behaviour and ensure that older patients are aware of the potential risks and benefits of using NSAIDs. Observational studies are needed to estimate rates of different predefined minor adverse effects associated with the use of oral NSAIDs in older people as are long-term studies of topical NSAIDs in those for whom oral NSAIDs are not appropriate.

MIB Abstract ID Number: 15635

PreMedline Identifier: 18505668

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance

Protective effects of NSAIDs on the development of Alzheimer disease.

Lead Author: Vlad SC

Additional Authors: Miller DR, Kowall NW, Felson DT.

Neurology., 2008-05-06, 70(19):1672-7.

Boston University School of Medicine, Clinical Epidemiology Research and Training Unit, 650 Albany St., Suite X200, Boston, MA 02118, USA. svlad@bu.edu

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer disease (AD), but observational studies and trials have offered contradictory results. Prior studies have also been relatively short and small. We examined the effects on AD risk of NSAID use for >5 years and of NSAIDs that suppress formation of A beta (1-42) amyloid in a large health care database. METHODS: Cases were veterans aged 55 years and older with incident AD using the US Veterans Affairs Health Care system. Matched controls were drawn from the same population. NSAID exposure was categorized into seven time periods: no use, <or=1 year, >1 but <or=2 years, and so on. Using conditional logistic regression, adjusted for race and comorbidities, we tested the association between AD development and the use of 1) any NSAID, 2) any NSAID excluding nonacetylated salicylates, 3) each NSAID class, 4) each individual NSAID, and 5) A beta (1-42)-suppressing NSAIDs. RESULTS: We identified 49,349 cases and 196,850 controls. Compared with no NSAID use, the adjusted odds ratios for AD among NSAID users decreased from 0.98 for <or=1 year of use (95% CI 0.95-1.00) to 0.76 for >5 years of use (0.68-0.85). For users of ibuprofen, it decreased from 1.03 (1.00-1.06) to 0.56 (0.42-0.75). Effects of other NSAID classes and individual NSAIDs were inconsistent. There was no difference between a group of A beta (1-42)-suppressing NSAIDs and others. Discussion: Long-term nonsteroidal anti-inflammatory drug (NSAID) use was protective against Alzheimer disease. Findings were clearest for ibuprofen. A beta (1-42)-suppressing NSAIDs did not differ from others.

MIB Abstract ID Number: 15636

PreMedline Identifier: 18458226

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance

Flexible porous metal-organic frameworks for a controlled drug delivery.

Lead Author: Horcajada P

Additional Authors: Serre C, Maurin G, Ramsahye NA, Balas F, Vallet-Regí M, Sebban M, Taulelle F, Férey G.

J Am Chem Soc., 2008-05-03, 130(21):6774-80. Epub 2008 May 3.

Institut Lavoisier, UMR CNRS 8180, Université de Versailles St-Quentin en Yvelines, 45 Avenue des Etats-Unis, 78035 Versailles Cedex, France.

Flexible nanoporous chromium or iron terephtalates (BDC) MIL-53(Cr, Fe) or M(OH)[BDC] have been used as matrices for the adsorption and in vitro drug delivery of Ibuprofen (or alpha- p-isobutylphenylpropionic acid). Both MIL-53(Cr) and MIL-53(Fe) solids adsorb around 20 wt % of Ibuprofen (Ibuprofen/dehydrated MIL-53 molar ratio = 0.22(1)), indicating that the amount of inserted drug does not depend on the metal (Cr, Fe) constitutive of the hybrid framework. Structural and spectroscopic characterizations are provided for the solid filled with Ibuprofen. In each case, the very slow and complete delivery of Ibuprofen was achieved under physiological conditions after 3 weeks with a predictable zero-order kinetics, which highlights the unique properties of flexible hybrid solids for adapting their pore opening to optimize the drug-matrix interactions.

MIB Abstract ID Number: 15637

PreMedline Identifier: 18454528

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance

Preparation and evaluation of immediate release ibuprofen solid dispersions using polyethylene glycol 4000.

Lead Author: Newa M

Additional Authors: Bhandari KH, Li DX, Kim JO, Yoo DS, Kim JA, Yoo BK, Woo JS, Choi HG, Yong CS.

Biol Pharm Bull. , 2008-05-01, 31(5):939-45.

College of Pharmacy, Yeungnam University, Gyongsan, 712-749, South Korea.

To improve its dissolution, ibuprofen solid dispersions (SDs) were prepared in a relatively easy and simple manner, characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FT-IR), and evaluated for solubility, in-vitro drug release and oral bioavailability of ibuprofen in rats. Loss of individual surface properties during melting and resolidification as revealed by SEM micrographs indicated the formation of effective SDs. Absence or shifting towards the lower melting temperature of the drug peak in SDs and physical mixtures in DSC study indicated the possibilities of drug-polymer interactions. FT-IR spectra showed the presence of drug crystalline in SDs. Quicker release of ibuprofen from SDs in rat intestine resulted in a significant increase in AUC and Cmax, and a significant decrease in Tmax over pure ibuprofen. Preliminary results from this study suggested that the preparation of fast dissolving ibuprofen SDs by low temperature melting method using polyethylene glycol 4000 (PEG 4000) as a meltable hydrophilic polymer carrier could be a promising approach to improve solubility, dissolution and absorption rate of ibuprofen.

MIB Abstract ID Number: 15638

PreMedline Identifier: 18451523

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance

Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung.

Lead Author: McCurnin D

Additional Authors: Seidner S, Chang LY, Waleh N, Ikegami M, Petershack J, Yoder B, Giavedoni L, Albertine KH, Dahl MJ, Wang ZM, Clyman RI.

Pediatrics. 2008 May;, 2008-05-01, 121(5):945-56.

Department of Pediatrics, University of Texas Health Science Center, San Antonio, Texas, USA.

OBJECTIVE: The goal was to study the pulmonary, biochemical, and morphologic effects of a persistent patent ductus arteriosus in a preterm baboon model of bronchopulmonary dysplasia. METHODS: Preterm baboons (treated prenatally with glucocorticoids) were delivered at 125 days of gestation (term: 185 days), given surfactant, and ventilated for 14 days. Twenty-four hours after birth, newborns were randomly assigned to receive either ibuprofen (to close the patent ductus arteriosus; n = 8) or no drug (control; n = 13). RESULTS: After treatment was started, the ibuprofen group had significantly lower pulmonary/systemic flow ratio, higher systemic blood pressure, and lower left ventricular end diastolic diameter, compared with the control group. There were no differences in cardiac performance indices between the groups. Ventilation index and dynamic compliance were significantly improved with ibuprofen. The improved pulmonary mechanics in ibuprofen-treated newborns were not attributable to changes in levels of surfactant protein B, C, or D, saturated phosphatidylcholine, or surfactant inhibitory proteins. There were no differences in tracheal concentrations of cytokines commonly associated with the development of bronchopulmonary dysplasia. The groups had similar messenger RNA expression of genes that regulate inflammation and remodeling in the lung. Lungs from ibuprofen-treated newborns were significantly drier (lower wet/dry ratio) and expressed 2.5 times more epithelial sodium channel protein than did control lungs. By 14 days after delivery, control newborns had morphologic features of arrested alveolar development (decreased alveolar surface area and complexity), compared with age-matched fetuses. In contrast, there was no evidence of alveolar arrest in the ibuprofen-treated newborns. CONCLUSIONS: Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization.

MIB Abstract ID Number: 15639

PreMedline Identifier: 18450898

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance

Ibuprofen linked to reduced AD risk

Lead Author: [none given]

CNS Drug News Pharmaceuticals , 2008-05-06

A study has associated the long-term use of ibuprofen and other drugs commonly used for aches and pains with a lower risk of Alzheimer's disease (AD). Previous research has shown conflicting results, but this is the longest study of its kind. For the study, which was published in the 6th May issue of Neurology (2008;70:1672-1677), researchers identified 49,349 US veterans aged 55 years and above who developed AD and 196,850 veterans without dementia. The study examined over five years of data and looked at the use of several non-steroidal anti-inflammatory drugs (NSAIDs). The veterans received medical care and prescriptions through the VA Health Care system.

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15645

*To access this Lexis-Nexis article the user must create an account.

Contact us for assistance

NSAIDS; Data on NSAIDS published by researchers at Kanazawa University

Lead Author: [none given]

Hospital Business Week , 2008-05-04, SECTION: EXPANDED REPORTING; Pg. 991

Current study results from the report, 'Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro,' have been published. According to recent research from Kanazawa, Japan, "The aggregation of alpha-synuclein (alphaS) in the brain has been implicated as a critical step in the development of Lewy body diseases (LBD) [Parkinson's disease (PD)/dementia with Lewy bodies (DLB)] and multiple system atrophy (MSA). The involvement of neuroinflammation and microglial activation has been emphasized in the pathogenesis of PD."

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15646

*To access this Lexis-Nexis article the user must create an account.

Contact us for assistance

ALZHEIMER DISEASE; Recent findings from University of Minnesota highlight research in Alzheimer disease

Lead Author: [none given]

Pharma Investments, Ventures & Law Weekly , 2008-04-30, SECTION: EXPANDED REPORTING; Pg. 227

According to recent research published in the journal Brain, "Non-steroidal anti-inflammatory agents (NSAIDs) are associated with a marked reduction in the risk of developing Alzheimers disease, a form of dementia characterized by the accumulation of amyloid plaques containing the amyloid-beta protein (A). Studies of the effects of NSAIDs upon the inflammatory response surrounding amyloid plaques and upon the generation of A beta from the amyloid precursor protein (APP) have led to two proposed mechanisms by which NSAIDs may protect against Alzheimers disease: one, the selective lowering of A beta 42 by a subset of NSAIDs; and two, the reduction of inflammation."

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15647

*To access this Lexis-Nexis article the user must create an account.

Contact us for assistance

Ask the doctor.(Clinical report).

Lead Author: Maurizio Fava.

Mind, Mood & Memory 4.5: p8(1). , 2008-05-01

Q Is it true that NSAIDs can protect people against Parkinson's disease?

A A number of studies have suggested that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Motrin, Advil) and naproxen (Aleve, Anaprox, Synflex) may help reduce risk of Parkinson's disease (PD). In one study published in the Nov. 6, 2007 issue of Neurology, investigators compared the history of NSAID use among individuals with recently diagnosed PD and a control group of similar individuals without the disease. They found that people who were regular users of non-aspirin NSAIDs (those who had taken two or more pills a week for at least a month) had a 48 percent lower risk of PD, while those who had taken nonaspirin NSAIDs regularly for two or more years had a 56 percent lower risk of the disease.

Some experts believe that non-aspirin NSAIDs may protect against PD by helping to inhibit inflammatory responses that might harm dopamine-producing cells in the brain. But further studies are needed to examine factors such as differences among individual NSAIDs, effective dosages and optimal conditions of use. Until more is known, it would be unwise to take these drugs on a regular basis to lower risk for PD, since NSAIDs can have serious side effects, including gastrointestinal disturbances, dizziness, headaches, and internal bleeding.

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15649

Gale Identifier: A177983374

* To access this Gale article the user must create an account.

Contact us for assistance
Pseudoephedrine & Ibuprofen
Alzheimer’s Disease & Ibuprofen

Health Buzz: Ibuprofen and Alzheimer's and Other Health News.

Lead Author: January W. Payne

U.S. News & World Report , 2008-05-06

Nonsteroidal anti-inflammatories might protect against Alzheimer's

Those who take ibuprofen on a regular basis for five years may be less likely to develop Alzheimer's disease as they get older, according to a new study.  And people who take nonsteroidal anti-inflammatory medicines in general may have a decreased risk. But the findings are not concrete enough to warrant advising patients to take a daily dose of ibuprofen, or any other type of NSAID, to ward off Alzheimer's, noted the researchers, led by Steven Vlad, a fellow in rheumatology at Boston University School of Medicine. Long-term use of NSAIDs carries a risk of gastrointestinal problems.

Still, "this trial is big enough and the results are good enough that it may reopen the debate--that we should do a prevention study with these medications," William Thies, vice president of medical and scientific relations for the Alzheimer's Association, told HealthDay.

Find out how to reduce your risk for dementia by shedding excess belly fat here, and learn the difference here between Alzheimer's disease and other types of dementia (http://usnews.healthline.com/channel/dementia.html).

MIB Abstract ID Number: 15651

*To access this Gale article the user must create an account.

Contact us for assistance

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice.

Lead Author: McKee AC

Additional Authors: Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A.

Brain Res., 2008-05-01, 1207:225-36. Epub 2008 Feb 16

Department of Neurology, Boston University School of Medicine, Boston, MA, USA.

We examined the effects of ibuprofen on cognitive deficits, Abeta and tau accumulation in young triple transgenic (3xTg-AD) mice. 3xTg-AD mice were fed ibuprofen-supplemented chow between 1 and 6 months. Untreated 3xTg-AD mice showed significant impairment in the ability to learn the Morris water maze (MWM) task compared to age-matched wild-type (WT) mice. The performance of 3xTg-AD mice was significantly improved with ibuprofen treatment compared to untreated 3xTg-AD mice. Ibuprofen-treated transgenic mice showed a significant decrease in intraneuronal oligomeric Abeta and hyperphosphorylated tau (AT8) immunoreactivity in the hippocampus. Confocal microscopy demonstrated co-localization of conformationally altered (MC1) and early phosphorylated tau (CP-13) with oligomeric Abeta, and less co-localization of oligomeric Abeta and later forms of phosphorylated tau (AT8 and PHF-1) in untreated 3xTg-AD mice. Our findings show that prophylactic treatment of young 3xTg-AD mice with ibuprofen reduces intraneuronal oligomeric Abeta, reduces cognitive deficits, and prevents hyperphosphorylated tau immunoreactivity. These findings provide further support for intraneuronal Abeta as a cause of cognitive impairment, and suggest that pathological alterations of tau are associated with intraneuronal oligomeric Abeta accumulation.

MIB Abstract ID Number: 15652

PreMedline Identifier: 18374906

*To access this PubMed use the PreMedline Identifier in the PubMed search field

Contact us for assistance
Age Onset Issue & Alzheimer's
Non-steroidal Anti-inflammatory Drug (NSAID) & Alzheimer's
Abbott Laboratories
Dalsy & Abbott
ALTER FARMACIA
Narfen & ALTER
Bausch & Lomb
Ibu-Vivimed & Bausch
Bayer Pharmaceutical
Midol IB & Bayer
Dorvial & Bayer
Bergen Brunswig Drug Company
Cap-Profen & Bergen
Tap-Profen & Bergen
BEXAL FARMACEUTICA
Ibubex & BEXAL
Bristol-Myers Squibb
Nuprin & Bristol-Myers

MEDICARE AND MEDICAID;Maryland Approves Medicaid Reimbursement for ActiPatch(R)

Lead Author: [none given]

Pharma Law Weekly , 2008-05-06, SECTION: EXPANDED REPORTING; Pg. 1677

Maryland Medicaid has approved medical necessity product reimbursement for ActiPatch(TM) for kidney-compromised patients. BioElectronics Corporation,

BioElectronics Corporation,  (Pink Sheets: BIEL), is the maker of ActiPatch, a revolutionary drug-free anti-inflammatory patch which accelerates healing (see also Medicare and Medicaid).

Many commonly used pharmaceutical agents including aspirin, ibuprofen (Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, Naprosyn) with regular use and most especially long-term use, can have serious complications such as ulcers and bleeding from the gastrointestinal tract. These medications have been known to worsen cardiovascular conditions, increase high blood pressure, kidney disease and diabetes.

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15653

*To access this Lexis-Nexis article the user must create an account.

Contact us for assistance
FARMASIERRA LABORATORIOS S.L.
Remidol & FARMASIERRA
FARMA LEPORI
Feminalin & FARMA
Intermed
Algofren & Intermed
Knoll Pharmaceutical Company
Ibu & Knoll
Rufen & Knoll
Vicoprofen / hydrocodone-ibuprofen & Knoll
LABORATORIOS ASOCIADOS NUPEL
Fiedosin & NUPEL
Major Pharmaceuticals
Childrens Ibuprofen Cold / ibuprofen and pseudoephedrine & Major Pharmaceuticals
Sup Pain Med & Major Pharmaceuticals
Marlop Pharmaceuticals Inc
Dolgesic & Marlop
McNeil
Motrin Children Cold/ ibuprofen and pseudoephedrine & McNeil
Motrin IB & McNeil

Scolr receives SPA to guide design of ER ibuprofen Phase III study

Lead Author: [none given]

Pharma Company Insight Pharmaceuticals , 2008-05-01

Scolr Pharmahas received a Special Protocol Assessment (SPA) from the FDA to guide the design of its pivotal Phase III dental pain study to support an NDA for an OTC 12-hour extended-release (ER) ibuprofen product. The company, which plans to initiate the study in the next 60 days, has also received positive results from the first of two bioequivalence trials and positive stability results for ER ibuprofen, providing further data to support the application to the FDA. The primary objective of the dental pain study is to evaluate the efficacy and safety of multiple doses of ER ibuprofen following extraction of third molar teeth.

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15656

*To access this Lexis-Nexis article the user must create an account.

Contact us for assistance
Motrin Children & McNeil
Motrin Junior Strength & McNeil
Motrin Infant & McNeil
Motrin IB Sinus / ibuprofen-pseudoephedrine & McNeil
Doctril & McNeil
NORMON
Ibuprofeno Normon & NORMON
OVATION Pharmaceuticals, Inc.
PDK Labs Inc
Advanced Pain Relief & PDK Labs
Perrigo, L. Company
Childrens Ibuprofen Berry & Perrigo
Ibuprofen & Perrigo
Pfizer U.S. Pharmaceuticals Group
Pediacare & Pfizer
Ratiopharm GmbH
Ibu-ratiopharm & Ratiopharm
Reckitt Benckiser
Nurofen Cold and Flu / ibuprofen and pseudoephedrine & Reckitt
Nurofen Plus / ibuprofen and codeine & Reckitt
Roberts/Hauck Pharmaceutical Corporation
Saleto-200 & Roberts/Hauck
Saleto-400 & Roberts/Hauck
Saleto-600 & Roberts/Hauck
Saleto-800 & Roberts/Hauck
SALVAT
Salvarina & SALVAT
Schering-Phough
Alivium & Schering-Phough
United Research Laboratories / Mutual Pharmaceutical Company
Uni-Pro & United Research
Watson Pharmaceuticals
Menadol & Watson
Reprexain / ibuprofen and hydrocodone & Watson
Woelm Pharma GmbH & Co.
Dolormin & Woelm
Wyeth Consumer Healthcare

16A Nonnarcotic analgesics.(SECTION 16: PAIN & PYREXIA).

Lead Author: [none given]

MPR Monthly Prescribing Reference 24.5: p316(5)., 2008-05-01

Full Text :COPYRIGHT 2008 Haymarket Media, Inc.

PRESCRIBING NOTES For NSAIDs for arthritis and dysmenorrhea see Sections 12A and 15D, respectively. The doses of these drugs should be individualized.

ADVIL Wyeth Cons. OTC

NSAID (propionic acid deny.). Ibuprofen 200mg; gelcaps; caplets; tabs; liqui-gels.

Indications: Minor aches and pain. Fever.

Adults: 200-400mg every 4-6 hours; max 1.2g/day.

Children: Use Children's or Junior form.

Contraindications: Aspirin allergy. 3rd trimester of pregnancy. Coronary artery bypass graft surgery.

Precautions: GI, hepatic, or renal disease. Dehydration. Pregnancy. Nursing mothers: not recommended.

Interactions: Avoid aspirin, other pain relievers. Increased risk of GI bleed with alcohol.

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15662

Gale Identifier: A180553840

* To access this Gale article the user must create an account.

Contact us for assistance
Advil & Wyeth

The Morning Call, Allentown, Pa., Spending Smart column: Change your brand allegiance

Lead Author: Gregory Karp

McClatchy-Tribune Regional News; The Morning Call, Allentown, Pa., 2008-05-04, The Morning Call

Distributed by McClatchy - Tribune Information Services.

May 4--People who regularly take prescription drugs know generics are a lot cheaper and generally as effective. But what many people might not know is that generic over-the-counter medications are a good deal too.

Store brands from chain drugstores, large discounters and warehouse clubs have the same active ingredients as name brands and must gain approval by the Food and Drug Administration, just like the brands that are household names.

So for medications, pain relievers, cough and cold remedies, vitamins and even first-aid supplies, consider buying store brands to save money. Some households could save hundreds of dollars a year.

*** Click Here to view the full text of this abstract ***

MIB Abstract ID Number: 15663

Factiva Identifier: KRTAA00020080504e4540000b

* To access this Factiva article the user must create an account.

Contact us for assistance
Advil Allergy Sinus / ibuprofen, pseudoephedrine HCl, and chlorpheniramine maleate & Wyeth
Advil Cold & Sinus/ pseudoephedrine HCI and ibuprofen & Wyeth
Advil PM / Diphenhydramine citrate and ibuprofen & Wyeth
Advil Liqui-Gels & Wyeth
Advil Migraine & Wyeth
Advil Multi-Symptom Cold / ibuprofen, pseudoephedrine HCl, and chlorpheniramine maleate & Wyeth
 
 

Please click here if you wish to return to the Table of Contents listing the most recent abstract database additions.

If you wish to know more about our MedIntelliBase Custom Email Alert service, please complete our request form or contact us directly for assistance. Our contact information is noted below.

Thank you for your interest in learning what our services can do to empower you -

Jordan Zornes

425-894-4147

Contact Us

or Vicky Hunsicker Sanko

425-869-8724

Contact Us


The Next Phase® Inc. - Medical Technology Consultancy & Publishing
Redmond, WA, USA
Website - www.MedIntelliBase.com


 
Alert Navigation